A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
Celgene
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc
CellCentric Ltd.
University of Southern California
Mayo Clinic
GlaxoSmithKline
Celgene
Sellas Life Sciences Group
Astex Pharmaceuticals, Inc.
Sun Yat-sen University
Kyowa Kirin Co., Ltd.
Hoosier Cancer Research Network
National Cancer Institute (NCI)
Alliance Foundation Trials, LLC.
Mayo Clinic
Oncopeptides AB
Hackensack Meridian Health
Novartis
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University of California, San Francisco
Dana-Farber Cancer Institute
Mayo Clinic
Bayer
University Health Network, Toronto
Leaf Vertical Inc.
AEterna Zentaris
University of Washington
European Myeloma Network B.V.
University of Michigan Rogel Cancer Center
Bayer
Threshold Pharmaceuticals
Mayo Clinic
University of Leeds
M.D. Anderson Cancer Center
University of Colorado, Denver
University of California, San Francisco
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.
SCRI Development Innovations, LLC
Teva Branded Pharmaceutical Products R&D, Inc.
Emory University
UNC Lineberger Comprehensive Cancer Center
Peter MacCallum Cancer Centre, Australia